Guizhou Bailing Group Pharmaceutical Co Ltd (002424) - Total Assets
Based on the latest financial reports, Guizhou Bailing Group Pharmaceutical Co Ltd (002424) holds total assets worth CN¥5.95 Billion CNY (≈ $871.40 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 002424 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Guizhou Bailing Group Pharmaceutical Co Ltd - Total Assets Trend (2007–2025)
This chart illustrates how Guizhou Bailing Group Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Guizhou Bailing Group Pharmaceutical Co (002424) shareholders funds for net asset value and shareholders' equity analysis.
Guizhou Bailing Group Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Guizhou Bailing Group Pharmaceutical Co Ltd's total assets of CN¥5.95 Billion consist of 44.0% current assets and 56.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.7% |
| Accounts Receivable | CN¥1.29 Billion | 20.8% |
| Inventory | CN¥665.85 Million | 10.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥424.14 Million | 6.8% |
| Goodwill | CN¥21.38 Million | 0.3% |
Asset Composition Trend (2007–2025)
This chart illustrates how Guizhou Bailing Group Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002424 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guizhou Bailing Group Pharmaceutical Co Ltd's current assets represent 44.0% of total assets in 2025, a decrease from 77.3% in 2007.
- Cash Position: Cash and equivalents constituted 5.7% of total assets in 2025, up from 3.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 5.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 20.8% of total assets.
Guizhou Bailing Group Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Guizhou Bailing Group Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Guizhou Bailing Group Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.95 | 1.00 | 1.52 |
| Quick Ratio | 0.70 | 0.70 | 1.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-143.73 Million | CN¥-4.97 Million | CN¥1.31 Billion |
Guizhou Bailing Group Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guizhou Bailing Group Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -13.1% |
| Total Assets | CN¥6.20 Billion |
| Market Capitalization | $938.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guizhou Bailing Group Pharmaceutical Co Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Guizhou Bailing Group Pharmaceutical Co Ltd's assets decreased by 13.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual total assets of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.20 Billion ≈ $906.89 Million |
-13.14% |
| 2024-12-31 | CN¥7.13 Billion ≈ $1.04 Billion |
-2.91% |
| 2023-12-31 | CN¥7.35 Billion ≈ $1.08 Billion |
+6.59% |
| 2022-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
+6.24% |
| 2021-12-31 | CN¥6.49 Billion ≈ $949.59 Million |
-7.73% |
| 2020-12-31 | CN¥7.03 Billion ≈ $1.03 Billion |
-0.23% |
| 2019-12-31 | CN¥7.05 Billion ≈ $1.03 Billion |
+17.95% |
| 2018-12-31 | CN¥5.98 Billion ≈ $874.52 Million |
+23.92% |
| 2017-12-31 | CN¥4.82 Billion ≈ $705.71 Million |
+13.85% |
| 2016-12-31 | CN¥4.24 Billion ≈ $619.85 Million |
+10.27% |
| 2015-12-31 | CN¥3.84 Billion ≈ $562.13 Million |
+7.75% |
| 2014-12-31 | CN¥3.57 Billion ≈ $521.70 Million |
+2.47% |
| 2013-12-31 | CN¥3.48 Billion ≈ $509.11 Million |
+7.38% |
| 2012-12-31 | CN¥3.24 Billion ≈ $474.12 Million |
+7.33% |
| 2011-12-31 | CN¥3.02 Billion ≈ $441.75 Million |
+7.83% |
| 2010-12-31 | CN¥2.80 Billion ≈ $409.66 Million |
+241.44% |
| 2009-12-31 | CN¥819.90 Million ≈ $119.98 Million |
+40.52% |
| 2008-12-31 | CN¥583.47 Million ≈ $85.38 Million |
+17.03% |
| 2007-12-31 | CN¥498.55 Million ≈ $72.95 Million |
-- |
About Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines … Read more